Thursday, 7th April 8th International Conference on Plasmodium vivax Research 2022

Please note, all times are listed in Australian Eastern Standard Time. 

Use a time zone converter to see your local time: https://www.timeanddate.com/worldclock/converter.html 

Chairs: Dionicia Gamboa & Andre Siquera

10-Year Follow-up study of Plasmodium vivax DBPII immune response in the Brazilian Amazon - Luzia Carvalho

Q&A - 10 minutes

Chairs: Manoj Duraisingh

Experimental tools for exploring liver-stage biology of Plasmodium vivax - Wanlapa Roobsoong

• In vivo assessment of Plasmodium vivax Chesson strain liver stage infection: novel studies to assess hypnozoite formation, persistence, activation and relapse. - Gigliola Zanghi
• Single-cell RNA profiling of Plasmodium vivax liver stages reveals parasite- and host- specific transcriptomic signatures and drug targets - Anthony A Ruberto
• A structure-function approach establishes a role for a member of the Plasmodium vivax Tryptophan Rich Antigen family in lipid binding and erythrocyte invasion - Prasun Kundu

Panel Q&A - 15 minutes

Chair: Chetan Chitnis

Towards a vaccine for Plasmodium Vivax: the future is bright - Angela Minassion

• Blocking P. vivax pre-erythrocytic infection with vaccines to prevent relapses - GaneshRam Visweswaran
• The road to aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ) for controlled human malaria infection - Sumana Chakravarty
• Malaria antigens are presented to CD8 T cells via the non-classical HLA-E - Caroline Junqueira

Panel Q&A - 15 minutes

• P. vivax schizont transcriptomes reveal PvTRAg variation linked to band3-mediated invasion in invasion inhibition assays - Katlijn De Meulenaere
• Full-length RNA-sequencing of Plasmodium vivax sporozoites provides an improved understanding of transcription at this stage. - Caitlin Bourke
• Plasmodium vivax infected Duffy-negative individuals exhibit low asexual parasitaemia and remain undetected silent reservoirs: implication on malaria elimination - Lemu Golassa
• Extracellular EphA2 acts as enhancing receptor for liver-stage infection by Plasmodium vivax - Sittinont Chainarin
• PlasmoDB and VectorBase: ‘Omics support for the global Vector and Plasmodium research communities - Susanne W Warrenfeltz

• First Plasmodium vivax malaria vaccine candidate to show in vivo efficacy against a blood-stage P. vivax Controlled Human Malaria challenge in UK adults - Mimi M Hou
• Identification of targets of protective antibody responses against Plasmodium vivax malaria using a multifunctional antibody profiling approach - Daniel Herbert Opi
• An integrative approach in identifying potential antigenic proteins of Plasmodium vivax via genome-wide screening - Utpalendu Paul
• Identification of naturally acquired transmission-blocking antibodies against Plasmodium vivax - Sataporn Thongpoon
• Evaluating the primate malaria parasites P. cynomolgi and P. knowlesi as in vitro models for understanding P. vivax invasion and vaccinology - Sheena Dass
• Evaluation of Plasmodium vivax antigens as a vaccine candidate to Plasmodium spp. - Luna de Lacerda
• Plasmodium cynomolgi as a means to study CD8 T cell immunity to P. vivax - Thomas Martinson
• Immunological profile and mechanism of action of γδT cells in Plasmodium vivax infection - Guilherme Castro
• Humoral immune response of neotropical primates naturally infected by Plasmodium spp. - Cristiana Ferreira Alves de Brito
• Antibodies can block the interaction between P. vivax AMA1 and the RON2 receptor and reveal a potential vaccine strategy - Daniel Herbert Opi
• CD71⁺-enriched extracellular vesicles from plasma of Plasmodium vivax patients contain antigenic parasite proteins - Iris Aparici Herraiz
• Production and characterization of a malaria transmission blocking vaccine candidate Pvs230D1-EPA for human clinical studies - David L. Narum

Chair: Carrie Lynch

Challenges of addressing vivax malaria in PNG - Moses Laman

Q&A - 10 minutes

Primaquine: which dose is best? - Rob Commons

• An ultra-short course, high-dose primaquine regimen to prevent Plasmodium vivax relapses following uncomplicated paediatric malaria due to any Plasmodium species - Sze-Ann Woon
• Results of the First Phase of an Operational Feasibility Study (TRuST) of Appropriate Plasmodium Vivax Radical Cure with Tafenoquine or Primaquine after Quantitative G6PD Testing in Brazil - Marcus Lacerda
• Artemisinin-independent inhibitory activity of Artemisia infusions against P. cynomolgi and P. vivax hepatic stages: microscopic evidence for disruption of parasite apicoplast - Shahin Tajeri

Panel Q&A - 15 minutes

P. vivax serological exposure markers: a novel approach for accelerating towards elimination - Rhea Longley

• Field evaluation of LAMP for detection of Plasmodium vivax infections in pregnancy in Papua New Guinea - Benishar Kombut
• Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria - Benedikt Ley
• Use of G6PD POC quantitative Biosensor in the malaria elimination program in Karen state, Myanmar - Germana Bancone

Panel Q&A - 15 minutes

• Adherence to vivax malaria treatment in high malaria endemic areas of Bangladesh - Mohammad Sharif Hossain
• Chloroquine resistance in Plasmodium vivax malaria: A systematic review in Indian settings - Vishnu Teja Nallapati
• Developing Paediatric Primaquine as a public good for malaria elimination - Bob WRJ Taylor
• How radical is radical cure? Site-specific biases in clinical trials underestimate the effect of radical cure on Plasmodium vivax hypnozoites - John H Huber
• Is there a place for community health workers in town? A case study in a rapidly expanding periurban area with high ethnic diversity and population mobility in Papua, Indonesia  - Annisa Rahmalia
• Modelling New Approach to Optimize medication Adherence, Treatment and Effective Management Initiative through integrated Evidence based Community Intervention for the Elimination of Malaria in Sub-Saharan Africa.   A field Experience and strategic approach to strengthening low cost effective evidence base community intervention in an Epidemic Control programme of funded by Fhi360/USAID/PEPFAR/SIDHAS in Southern Nigeria. - Benjamin Dr Bob
• QSAR-based virtual screening coupled to experimental validation identifies 4-aminoquinoline active against multidrug-resistant P. falciparum and transmission stages in vitro - Leticia T Ferreira
• Plasmodium Vivax: progress in screening and impact on Drug Discovery and Development - Brice Campo
• Stakeholders’ insights on optimising the introduction of new global guidelines for radical cure of P. vivax malaria  - VARUNIKA S H RUWANPURA
• Bayesian Within-host Modelling of Red Blood Cell Dynamics and Primaquine-induced Haemolysis in G6PD Deficiency - Parinaz Mehdipour
• Effect of Adherence to Primaquine on the Risk of Plasmodium Vivax Recurrence: A Systematic Review and Individual Patient Data Meta-Analysis - Parinaz Mehdipour
• Feasibility and acceptability of phone follow-up to improve adherence to radical cure treatment of P. vivax malaria in Papua Indonesia - Annisa Rahmalia
• Assessing the effect of primaquine daily dose on tolerability and safety in patients with Plasmodium vivax: an individual patient data meta-analysis   - Megha Rajasekhar

• Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study) - Jose Diego Brito-Sousa
• A step closer to Next Generation RDT prototype development for diagnosing and prognosis of Plasmodium vivax malaria  - Shalini Aggarwal
• Repeatability and reproducibility of a handheld quantitative G6PD diagnostic - Benedikt Ley
• The cost-effectiveness of tafenoquine following G6PD screening in Brazil: a transmission model analysis - Angela Devine
• Malaria transmission structure in the Peruvian Amazon through antibody signatures to Plasmodium vivax - Jason Rosado
• Assessment of IgG3 as a Serological Exposure Marker for Plasmodium vivax Malaria in Moderate Endemic Areas  - Yanie Tayipto
• Evaluation of a novel hemozoin-based assay for rapid detection of malaria parasites at a tertiary care hospital in India - Kavitha Saravu
• Developing sero-diagnostic tests to facilitate Plasmodium vivax Serological Test-and-Treat approaches: modelling the balance between public health impact and overtreatment - Thomas Obadia
• Evaluation of a Novel Point-of-Care Diagnostic to Identify Glucose-6-Phosphate Dehydrogenase Deficiency in India - Abhijit Sharma
• Operational feasibility of integrating glucose-6-phosphate dehydrogenase point-of-care testing into malaria case management: evidence from Vietnam and Lao PDR - Emily Gerth-Guyette
• Measuring glucose-6-phosphate dehydrogenase deficiency in Ethiopia: multiple methods for measurement, point-of-care diagnostic performance, and implications for malaria case management - Wondimagegn Adissu
• G6PD deficiency: genotype/phenotype associations and implications for diagnostics - Gonzalo Domingo
• Incremental performance of new lactate dehydrogenase-based Plasmodium vivax rapid diagnostic tests - Allison Golden
• G6PD Deficiency Prevalence across Indonesia: Distribution Map and Normal Activity Approximation - Arkasha Sadhewa
• The last kilometre – what are stakeholders priorities to achieve vivax elimination? - Manash Shrestha
• Development of a new Plasmodium vivax LDH secondary diagnostic standard using P. knowlesi orthologue replacement - Giulia Pianta
• Detection of different species of Plasmodium in saliva using Real-time PCR and Droplet Digital PCR - TAIS N SOUSA
• Application of serological markers of exposure for the assessment of the spatial heterogeneity of Plasmodium vivax infections and risk of recurrent infections in young Papua New Guinean children - Shazia Ruybal-Pesántez
• A fluorometric assay to determine the protective effect of Glucose-6-Phosphate Dehydrogenase (G6PD) against a Plasmodium spp. infection in females heterozygous for the G6PD gene: Proof of concept in Plasmodium falciparum - Angela AR Rumaseb
• Post-treatment hemozoin levels in malaria patients in Papua New Guinea quantified using rotating-crystal magneto-optical detection - Agnes Orban